2025年4月7日 星期一
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2023, Vol. 29 Issue (12): 2092-2097    DOI: 10.3969/j.issn.1006-6233.2023.12.030
  药物与临床 本期目录 | 过刊浏览 | 高级检索 |
美托洛尔缓释片联合沙库巴曲缬沙坦钠片治疗高血压合并心衰患者临床疗效的观察
庞明群1, 方茹2, 程永凤3
1.安徽省合肥市第一人民医院西区药剂科, 安徽 合肥 230031
2.安徽医科大学第一附属医院东城院区重症医学科, 安徽 合肥 231600
3.安徽医科大学临床医学院药学与生物医学工程学院, 安徽 合肥 230031
Clinical Observation on the Efficacy of Metoprolol Sustained-Release Tablets Combined with Sacubitril Valsartan Tablets in the Treatment of Hypertension Complicated with Heart Failure
PANG Mingqun, et al
West District of Hefei First People's Hospital, Anhui Hefei 230031, China
全文: PDF (1217 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的: 探究美托洛尔缓释片联合沙库巴曲缬沙坦钠片治疗高血压合并心衰的临床疗效。方法: 选取本院2020年1月至2023年1月收治的135例高血压合并心衰患者,按就诊顺序采取单双号法分为68例倍他乐克组[单号,采取常规治疗+美托洛尔缓释片(商品名:倍他乐克)]和67例诺欣妥组[双号,在倍他乐克组基础上+沙库巴曲缬沙坦片(商品名:诺欣妥)]。比较两组治疗疗效,治疗前后血压及心率,心功能指标,血管内皮功能及血清肌钙蛋白Ⅰ(cTnI)和氨基末端脑钠肽(NT-BNP)水平,记录两组治疗期间不良反应发生情况。结果: 诺欣妥组总有效率高于倍他乐克组(97.01%vs86.76%)(P<0.05);治疗后,两组收缩压,舒张压和心率,心功能指标LVESD和LVEDD,ET,cTnI和NT-BNP均降低(P<0.05),LVEF,NO和CGRP均增加(P<0.05),两组间治疗前后差值具有统计学意义(P<0.05);两组不良发应发生情况比较差异无统计学意义(P>0.05)。结论: 美托洛尔缓释片与沙库巴曲缬沙坦钠联合治疗高血压并心衰的疗效显著,该疗法可有效控制血压,改善心脏功能和血管内皮功能,同时降低了cTnI和NT-BNP水平,值得在临床实践中推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 高血压心力衰竭美托洛尔缓释片沙库巴曲缬沙坦片    
AbstractObjective: To explore the clinical efficacy of metoprolol succinate sustained-release tablets combined with sacubitril valsartan tablets in the treatment of hypertension complicated with heart failure. Methods: A total of 135 patients with hypertension complicated with heart failure admitted to our hospital from January 2020 to January 2023 were selected. According to the order of admission, they were divided into the Bisoprolol Group (odd numbers, conventional treatment + metoprolol sustained-release tablets) with 68 cases and the Sacubitril Group (even numbers, based on the Bisoprolol Group + sacubitril valsartan tablets) with 67 cases, using single and double numbers. The treatment effects, blood pressure, heart rate, cardiac function indicators, vascular endothelial function, and levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-BNP) before and after treatment were compared between the two groups. Adverse reactions during the treatment period were recorded. Results: The total effective rate in the Sacubitril Group was higher than that in the Bisoprolol Group (97.01% vs 86.76%) (P<0.05). After treatment, both groups showed a significant reduction in systolic and diastolic blood pressure, heart rate, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), endothelin (ET), cTnI, and NT-BNP (P<0.05). Left ventricular ejection fraction (LVEF), nitric oxide (NO), and calcitonin gene-related peptide (CGRP) increased (P<0.05). The differences before and after treatment between the two groups were statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of metoprolol sustained-release tablets and sacubitril valsartan sodium is significantly effective in treating hypertension with heart failure. This treatment can effectively control blood pressure, improve cardiac function and vascular endothelial function, and reduce levels of cTnI and NT-BNP. It is worthy of promotion and application in clinical practice.
Key wordsMetoprolol succinate sustained-release tablets    Sacubitril valsartan tablets
    
基金资助:安徽省高等学校自然科学研究项目,(编号:KJ2021A1227)
通讯作者: 程永凤   
引用本文:   
庞明群, 方茹, 程永凤. 美托洛尔缓释片联合沙库巴曲缬沙坦钠片治疗高血压合并心衰患者临床疗效的观察[J]. 河北医学, 2023, 29(12): 2092-2097.
PANG Mingqun, et al. Clinical Observation on the Efficacy of Metoprolol Sustained-Release Tablets Combined with Sacubitril Valsartan Tablets in the Treatment of Hypertension Complicated with Heart Failure. HeBei Med, 2023, 29(12): 2092-2097.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2023.12.030     或     http://www.hbyxzzs.cn/CN/Y2023/V29/I12/2092
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发